S&P 500   4,205.52 (+0.00%)
DOW   33,042.78 (-0.15%)
QQQ   349.98 (+0.45%)
AAPL   177.30 (+1.07%)
MSFT   331.21 (-0.50%)
META   262.52 (+0.18%)
GOOGL   123.67 (-0.75%)
AMZN   121.66 (+1.29%)
TSLA   201.16 (+4.14%)
NVDA   401.11 (+2.99%)
NIO   7.41 (-3.77%)
BABA   78.67 (-2.84%)
AMD   125.27 (-1.39%)
T   15.64 (+0.90%)
F   12.59 (+4.14%)
MU   71.69 (-3.03%)
CGC   0.85 (-3.08%)
GE   102.40 (-0.33%)
DIS   87.82 (-0.53%)
AMC   4.63 (-0.22%)
PFE   37.01 (-1.57%)
PYPL   62.05 (+3.04%)
NFLX   392.98 (+3.72%)
S&P 500   4,205.52 (+0.00%)
DOW   33,042.78 (-0.15%)
QQQ   349.98 (+0.45%)
AAPL   177.30 (+1.07%)
MSFT   331.21 (-0.50%)
META   262.52 (+0.18%)
GOOGL   123.67 (-0.75%)
AMZN   121.66 (+1.29%)
TSLA   201.16 (+4.14%)
NVDA   401.11 (+2.99%)
NIO   7.41 (-3.77%)
BABA   78.67 (-2.84%)
AMD   125.27 (-1.39%)
T   15.64 (+0.90%)
F   12.59 (+4.14%)
MU   71.69 (-3.03%)
CGC   0.85 (-3.08%)
GE   102.40 (-0.33%)
DIS   87.82 (-0.53%)
AMC   4.63 (-0.22%)
PFE   37.01 (-1.57%)
PYPL   62.05 (+3.04%)
NFLX   392.98 (+3.72%)
S&P 500   4,205.52 (+0.00%)
DOW   33,042.78 (-0.15%)
QQQ   349.98 (+0.45%)
AAPL   177.30 (+1.07%)
MSFT   331.21 (-0.50%)
META   262.52 (+0.18%)
GOOGL   123.67 (-0.75%)
AMZN   121.66 (+1.29%)
TSLA   201.16 (+4.14%)
NVDA   401.11 (+2.99%)
NIO   7.41 (-3.77%)
BABA   78.67 (-2.84%)
AMD   125.27 (-1.39%)
T   15.64 (+0.90%)
F   12.59 (+4.14%)
MU   71.69 (-3.03%)
CGC   0.85 (-3.08%)
GE   102.40 (-0.33%)
DIS   87.82 (-0.53%)
AMC   4.63 (-0.22%)
PFE   37.01 (-1.57%)
PYPL   62.05 (+3.04%)
NFLX   392.98 (+3.72%)
S&P 500   4,205.52 (+0.00%)
DOW   33,042.78 (-0.15%)
QQQ   349.98 (+0.45%)
AAPL   177.30 (+1.07%)
MSFT   331.21 (-0.50%)
META   262.52 (+0.18%)
GOOGL   123.67 (-0.75%)
AMZN   121.66 (+1.29%)
TSLA   201.16 (+4.14%)
NVDA   401.11 (+2.99%)
NIO   7.41 (-3.77%)
BABA   78.67 (-2.84%)
AMD   125.27 (-1.39%)
T   15.64 (+0.90%)
F   12.59 (+4.14%)
MU   71.69 (-3.03%)
CGC   0.85 (-3.08%)
GE   102.40 (-0.33%)
DIS   87.82 (-0.53%)
AMC   4.63 (-0.22%)
PFE   37.01 (-1.57%)
PYPL   62.05 (+3.04%)
NFLX   392.98 (+3.72%)
NASDAQ:NKTR

Nektar Therapeutics (NKTR) Stock Forecast, Price & News

$0.62
-0.01 (-1.46%)
(As of 04:32 PM ET)
Compare
Today's Range
$0.61
$0.65
50-Day Range
$0.63
$1.03
52-Week Range
$0.60
$5.18
Volume
3.02 million shs
Average Volume
3.81 million shs
Market Capitalization
$117.90 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$2.40

Nektar Therapeutics MarketRank™ Forecast

Analyst Rating
Hold
1.60 Rating Score
Upside/​Downside
285.2% Upside
$2.40 Price Target
Short Interest
Bearish
5.34% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-1.77
Upright™ Environmental Score
News Sentiment
-0.01mentions of Nektar Therapeutics in the last 14 days
Based on 6 Articles This Week
Insider Trading
Selling Shares
$21,709 Sold Last Quarter
Proj. Earnings Growth
Growing
From ($1.15) to ($0.90) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.07 out of 5 stars

Medical Sector

584th out of 1,009 stocks

Pharmaceutical Preparations Industry

285th out of 494 stocks


NKTR stock logo

About Nektar Therapeutics (NASDAQ:NKTR) Stock

Nektar Therapeutics is a research-based biopharmaceutical company which engages in discovering and developing medicines in areas of unmet medical need. Its research and development pipeline of new investigational drugs includes therapies for oncology, immunology and virology. The firm focuses on using new chemistry approaches to make medicines to treat cancer and autoimmune diseases. The company was founded in 1990 and is headquartered in San Francisco, CA.

Receive NKTR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Nektar Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

NKTR Stock News Headlines

Howard Robin seeks another turnaround at Nektar
BREAKING: Tiny biotech successfully treats blindness
There's a tiny biotech in Cambridge that's using a breakthrough technology to treat blindness. This company has already shown success in human trials... And Our research shows that anyone who gets in today could see a 46,751% return.
BREAKING: Tiny biotech successfully treats blindness
There's a tiny biotech in Cambridge that's using a breakthrough technology to treat blindness. This company has already shown success in human trials... And Our research shows that anyone who gets in today could see a 46,751% return.
Jefferies upgrades Nektar Therapeutics (NKTR) to a Hold
Nektar Therapeutics Reports First Quarter 2023 Financial Results
Nektar Therapeutics Q1 Loss increases, misses estimates
Brokerages Set Nektar Therapeutics (NASDAQ:NKTR) PT at $3.08
Goldman Sachs Remains a Sell on Nektar Therapeutics (NKTR)
Mizuho Securities Remains a Hold on Nektar Therapeutics (NKTR)
See More Headlines
Receive NKTR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Nektar Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

NKTR Company Calendar

Last Earnings
2/28/2023
Today
5/30/2023
Next Earnings (Estimated)
8/03/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceuticals
Sector
Medical
Current Symbol
NASDAQ:NKTR
CUSIP
64026810
Employees
740
Year Founded
1990

Price Target and Rating

Average Stock Price Forecast
$2.40
High Stock Price Forecast
$3.00
Low Stock Price Forecast
$1.00
Forecasted Upside/Downside
+287.5%
Consensus Rating
Hold
Rating Score (0-4)
1.60
Research Coverage
5 Analysts

Profitability

Net Income
$-368,200,000.00
Net Margins
-467.00%
Pretax Margin
-463.59%

Debt

Sales & Book Value

Annual Sales
$92.06 million
Book Value
$1.95 per share

Miscellaneous

Free Float
182,839,000
Market Cap
$117.20 million
Optionable
Optionable
Beta
1.09

Social Links


Key Executives

  • Howard W. RobinHoward W. Robin
    President, Chief Executive Officer & Director
  • Sandra A. Gardiner
    Chief Financial & Accounting Officer
  • Mary Tagliaferri
    Chief Medical Officer
  • Jonathan ZalevskyJonathan Zalevsky
    Chief Research & Development Officer
  • Mark A. Wilson
    Secretary, Chief Legal Officer & Senior VP













NKTR Stock - Frequently Asked Questions

Should I buy or sell Nektar Therapeutics stock right now?

5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Nektar Therapeutics in the last year. There are currently 2 sell ratings and 3 hold ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" NKTR shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in NKTR, but not buy additional shares or sell existing shares.
View NKTR analyst ratings
or view top-rated stocks.

What is Nektar Therapeutics' stock price forecast for 2023?

5 brokerages have issued 12-month price objectives for Nektar Therapeutics' shares. Their NKTR share price forecasts range from $1.00 to $3.00. On average, they anticipate the company's stock price to reach $2.40 in the next year. This suggests a possible upside of 287.5% from the stock's current price.
View analysts price targets for NKTR
or view top-rated stocks among Wall Street analysts.

How have NKTR shares performed in 2023?

Nektar Therapeutics' stock was trading at $2.26 at the start of the year. Since then, NKTR stock has decreased by 72.6% and is now trading at $0.6193.
View the best growth stocks for 2023 here
.

When is Nektar Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, August 3rd 2023.
View our NKTR earnings forecast
.

How were Nektar Therapeutics' earnings last quarter?

Nektar Therapeutics (NASDAQ:NKTR) posted its earnings results on Tuesday, February, 28th. The biopharmaceutical company reported ($0.32) earnings per share for the quarter, beating the consensus estimate of ($0.43) by $0.11. The biopharmaceutical company earned $22.02 million during the quarter, compared to analysts' expectations of $22.21 million. Nektar Therapeutics had a negative trailing twelve-month return on equity of 84.36% and a negative net margin of 467.00%. The firm's revenue for the quarter was down 11.9% on a year-over-year basis. During the same quarter in the prior year, the business posted ($0.79) earnings per share.

What ETFs hold Nektar Therapeutics' stock?

ETFs with the largest weight of Nektar Therapeutics (NASDAQ:NKTR) stock in their portfolio include Virtus LifeSci Biotech Products ETF (BBP), Invesco Nasdaq Future Gen 200 ETF (QQQS) and Inspire Small/Mid Cap ETF (ISMD) and

What is Howard W. Robin's approval rating as Nektar Therapeutics' CEO?

46 employees have rated Nektar Therapeutics Chief Executive Officer Howard W. Robin on Glassdoor.com. Howard W. Robin has an approval rating of 81% among the company's employees.

What other stocks do shareholders of Nektar Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Nektar Therapeutics investors own include Micron Technology (MU), NVIDIA (NVDA), Alibaba Group (BABA), Gilead Sciences (GILD), Intel (INTC), Pfizer (PFE), Advanced Micro Devices (AMD), Bristol-Myers Squibb (BMY), Netflix (NFLX) and Incyte (INCY).

What is Nektar Therapeutics' stock symbol?

Nektar Therapeutics trades on the NASDAQ under the ticker symbol "NKTR."

Who are Nektar Therapeutics' major shareholders?

Nektar Therapeutics' stock is owned by a number of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (18.79%), State Street Corp (3.69%), Pictet Asset Management SA (1.97%), Geode Capital Management LLC (1.86%), Renaissance Technologies LLC (1.59%) and AQR Capital Management LLC (1.45%). Insiders that own company stock include Curet Myriam, Gil M Labrucherie, Gil M Labrucherie, Howard W Robin, Howard W Robin, Jeffrey Robert Ajer, Jillian B Thomsen, Jillian B Thomsen, John Northcott, Jonathan Zalevsky, Karin Eastham, Mark Andrew Wilson, Myriam Curet, R Scott Greer and Robert Chess.
View institutional ownership trends
.

How do I buy shares of Nektar Therapeutics?

Shares of NKTR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Nektar Therapeutics' stock price today?

One share of NKTR stock can currently be purchased for approximately $0.62.

How much money does Nektar Therapeutics make?

Nektar Therapeutics (NASDAQ:NKTR) has a market capitalization of $117.20 million and generates $92.06 million in revenue each year. The biopharmaceutical company earns $-368,200,000.00 in net income (profit) each year or ($2.21) on an earnings per share basis.

How many employees does Nektar Therapeutics have?

The company employs 740 workers across the globe.

How can I contact Nektar Therapeutics?

Nektar Therapeutics' mailing address is 455 MISSION BAY BOULEVARD SOUTH, SAN FRANCISCO CA, 94158. The official website for the company is www.nektar.com. The biopharmaceutical company can be reached via phone at (415) 482-5300, via email at investors@nektar.com, or via fax at 415-339-5300.

This page (NASDAQ:NKTR) was last updated on 5/30/2023 by MarketBeat.com Staff

My Account -